Personalized molecular therapy shows promising results for people with advanced lung cancer
2010-12-10
(Press-News.org) A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.
Epigenetics therapy is an approach designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, was designed to evaluate whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib in patients with advanced lung cancer.
This study was a randomized phase II placebo controlled clinical trial in advanced lung cancer examining whether entinostat in combination with erlotinib is better than erlotinib alone and whether it can be safely tolerated by patients. As part of the clinical trial, patients underwent an analysis of various tissue and blood biomarkers. The results demonstrated that patients with elevated E-cadherin (a molecular marker) who were administered entinostat in combination with erlotinib had a significantly improved overall survival as compared to patients treated with erlotinib alone. Approximately 40 percent of non-small cell lung cancer patients have elevated E-cadherin.
These findings highlight the importance of patient selection in defining treatment approaches in lung cancer and, if confirmed, could provide benefit to patients who have or develop resistance to current molecular targeted therapy.
"The results of ENCORE 401 identified a subset of lung cancer patients for whom the combination of epigenetic therapy, entinostat and molecular targeted therapy, erlotinib, achieved promising results," Robert M. Jotte, M.D., Ph.D., principal investigator of the study, director of thoracic oncology at Rocky Mountain Cancer Center Midtown Division in Denver and developmental co-chair of US Oncology Lung Committee, said. "These results support the ongoing drive toward using personalized health care to dictate therapy in an attempt to optimize outcomes. A follow-up study to advance the combination toward registration is planned."
###
The abstract "Molecular Analysis Identifies a Subset of Non-small Cell Lung Cancer Patients With Differential Sensitivity to Histone Deacetylase Inhibitor (hdaci)/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (egfr-tki) Treatment" will be presented at 2:15 p.m. Central time on Friday, December 10, 2010. To speak with Robert M. Jotte, M.D., Ph.D., please call Beth Bukata or Nicole Napoli on December 9-10, 2010, in the press office, the Astoria Room, at the Hilton Chicago at 312-294-6736. You may also e-mail them at bethb@astro.org or nicolen@astro.org.
END
ELSE PRESS RELEASES FROM THIS DATE:
2010-12-10
– Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.
Paclitaxel/carboplatin are commonly ...
2010-12-10
A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.
In this study, researchers compared two treatments ...
2010-12-10
Patients treated by Welsh (UK) hospitals for upper gastrointestinal (GI) bleeding were 41% more likely die if they were admitted on a public holiday and 13% more likely if it was at the weekend, according to research in the January issue of Alimentary Pharmacology and Therapeutics.
Researchers who analysed the records of 22,299 people admitted a total of 24,421 times between 1999 and 2007 also found that admissions, but not death rates, were significantly influenced by social deprivation.
"The higher death rates for weekend and public holiday admissions could not ...
2010-12-10
What algorithms should an air defense system work with? Particle swarm algorithms if there are ten targets to be hit. If there are more than ten targets, greedy algorithms work best. These findings are presented by researcher Fredrik Johansson at the Informatics Research Centre, University of Skövde, in Sweden.
So-called TEWA systems (Threat Evaluation & Weapon Allocation) are used to protect strategic targets from enemy attacks, such as an airfield that needs to be protected from incoming missiles.
The systems discover threats, evaluates the threats, and aims the defender's ...
2010-12-10
Georgia, US - A team of Bioengineers in the United States have modified a strain of bacteria to increase its ability to produce ethanol. The research, published in Biotechnology and Bioengineering, reveals how adaptation and metabolic engineering can be combined for strain improvement, a positive development for the biofuel industry.
The team focused their research on Zymomonas mobilis, a bacterium noted for its bio-ethanol producing potential. However, the team believed that ethanol production could be increased through improvement of xylose fermentation.
"Zymomonas ...
2010-12-10
College students whose parents have remained married to each other are faring better financially than their peers with divorced or remarried parents, according to new research from Rice University and the University of Wisconsin.
The study, published in the December Journal of Family Issues, found that divorced parents contributed about a third of what married parents contributed to their children's education even though the divorced parents' incomes are about half as much as their married peers'; remarried parents contributed about half of what married parents contributed, ...
2010-12-10
Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine researchers in The Foreman Foundation Research Laboratory.
"Preventing vessels from developing in tumors is one way to stop them from growing," said lead author Gavin Robertson, Ph.D., professor of pharmacology, pathology, dermatology and surgery. "However, the identity of the proteins secreted by tumors cells enabling the angiogenesis process to ...
2010-12-10
When it comes to health care blue lights, are usually most useful on the top of ambulances but now new research led by the University of Warwick has found a way to use blue light to activate what could be a highly potent platinum-based cancer treatment.
Research led by the University of Warwick, along with researchers from Ninewells Hospital Dundee, and the University of Edinburgh, have found a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use "light activation" to kill cancer ...
2010-12-10
Watching a television show from a digital video recorder (DVR) gives viewers a chance to skip commercials, but new research finds that owning a DVR does not influence the demand for advertised products despite its ad-skipping feature.
In fact, only a small percentage of ads were fast-forwarded by DVR users who participated in the study, and even that did not have an adverse effect on sales.
The research was conducted by Jean-Pierre Dube from the University of Chicago Booth School of Business, Bart Bronnenberg from Tilburg University in The Netherlands and Carl Mela ...
2010-12-10
ANN ARBOR, Mich. — A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.
The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib as a front-line treatment of patients with myeloma, a type of cancer that arises in the plasma cells.
Initial results of the phase I study were ...
LAST 30 PRESS RELEASES:
[Press-News.org] Personalized molecular therapy shows promising results for people with advanced lung cancer
